69:HKEXShangri-La Asia Limited Analysis
Data as of 2026-05-21 - not real-time
¥6,556.00
Latest Price
5/10Risk
Risk Level: Medium
Executive Summary
JEOL Ltd. is trading just above its 20‑day simple moving average, aligning with a broader bullish trend despite a bearish MACD histogram and a neutral RSI that suggests limited short‑term momentum. Support around the 6100 level provides a cushion, while the next resistance near 7100 caps upside potential in the near term. The stock exhibits a low beta, indicating modest sensitivity to market swings, yet 30‑day volatility remains elevated, reflecting price swings typical for high‑tech equipment makers. Valuation metrics are compelling: the company’s PE ratio sits well below the industry average, and a dividend yield of over 2% adds income appeal. However, revenue has contracted sharply, highlighting execution risk in a competitive global market. The discounted cash‑flow model appears to price the stock significantly lower than its current level, suggesting possible overvaluation from a pure cash‑flow perspective.
Looking ahead, JEOL’s solid return on equity, sustainable payout ratio, and diversified exposure across scientific, industrial, and medical segments support a longer‑term case for accumulation. The combination of relative valuation attractiveness, dividend sustainability, and sector demand trends outweighs the near‑term technical headwinds, positioning the stock as a favorable buy for investors with a medium to long horizon.
Looking ahead, JEOL’s solid return on equity, sustainable payout ratio, and diversified exposure across scientific, industrial, and medical segments support a longer‑term case for accumulation. The combination of relative valuation attractiveness, dividend sustainability, and sector demand trends outweighs the near‑term technical headwinds, positioning the stock as a favorable buy for investors with a medium to long horizon.
Market Outlook
Short Term
< 1 yearNeutral
Model confidence: 6/10
Key Factors
- Price hugging the 20‑day SMA with support intact
- Neutral RSI and bearish MACD indicating limited upside
- Stable trading volume and low beta reducing market‑wide shock exposure
Medium Term
1–3 yearsNeutral
Model confidence: 5/10
Key Factors
- PE advantage versus industry peers
- Attractive dividend yield with a comfortable payout ratio
- Revenue contraction that could pressure earnings growth
Long Term
> 3 yearsPositive
Model confidence: 7/10
Key Factors
- Diversified product portfolio serving high‑growth scientific and medical markets
- Strong ROE and cash‑flow generation supporting dividend sustainability
- Relative undervaluation and lower beta offering defensive characteristics
Key Metrics & Analysis
Financial Health
Revenue Growth-17.90%
Profit Margin12.32%
P/E Ratio15.1
ROE15.70%
ROA7.00%
Debt/Equity18.70
P/B Ratio2.3
Op. Cash Flow¥16.0B
Free Cash Flow¥1.9B
Industry P/E38.8
Technical Analysis
TrendBullish
RSI51.7
Support¥6,100.00
Resistance¥7,100.00
MA 20¥6,556.80
MA 50¥6,252.30
MA 200¥5,471.59
MACDBearish
VolumeStable
Fear & Greed Index90.29
Valuation
Fair Value¥753.37
Target Price¥7,000.00
Upside/Downside6.77%
GradeUndervalued
TypeBlend
Dividend Yield2.10%
Risk Assessment
Beta0.71
Volatility52.94%
Sector RiskMedium
Reg. RiskLow
Geo RiskMedium
Currency RiskMedium
Liquidity RiskLow
Similar Tickers
This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.